Widely used GLP-1 receptor agonists, commonly prescribed for type 2 diabetes and obesity, may be associated with a small increase in colorectal cancer risk, according to a recent meta-analysis discussed by oncology expert David Kerr, MD, of the University of Oxford.
The analysis pooled data from seven retrospective cohort studies involving more than 5 million individuals. Researchers found a slight but statistically significant increase in colorectal cancer risk among patients using GLP-1 drugs.
GLP-1 medications—such as those used for weight loss and diabetes—are often expected to reduce cancer risk because they lower body weight and adiposity, both known risk factors for several cancers. However, the findings highlight ongoing uncertainty in the literature about their long-term effects on cancer risk.
Experts emphasize that the evidence is observational and not definitive, and further prospective studies are needed. For now, clinicians may consider individual patient risk factors—such as family history of colorectal cancer—when weighing the benefits of GLP-1 therapies against potential risks.